無料セミナー : 2018年11月27日『オンコロジーにおける遺伝子治療・CAR-T細胞療法』 DelveInsight Business Research LLP共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非アルコール性脂肪性肝炎 (NASH):市場考察、疫学および市場予測

Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast - 2027

発行 DelveInsight Business Research LLP 商品コード 535889
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.49円で換算しております。
Back to Top
非アルコール性脂肪性肝炎 (NASH):市場考察、疫学および市場予測 Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast - 2027
出版日: 2018年01月01日 ページ情報: 英文 100 Pages
概要

当レポートでは、非アルコール性脂肪性肝炎 (NASH) の疾病概要および主要7市場 (米国、EU5ヶ国、日本) における疫学と市況について分析しており、治療薬市場の収益、実施されている治療法、および疫学的予測 (有病者数など) を提供しています。

目次

第1章 イントロダクション

第2章 非アルコール性脂肪性肝炎 (NASH) 市場の概要

第3章 非アルコール性脂肪性肝炎 (NASH) の市場シェア分布:主要7ヶ国市場

第4章 非アルコール性脂肪性肝炎 (NASH) の市場シェア分布予測:主要7ヶ国市場

第5章 非アルコール性脂肪性肝炎 (NASH)

  • イントロダクション
  • タイプ
  • NASHの分類:繊維症の病期
  • 病因
  • 病態生理学
  • 症状
  • 診断

第6章 疫学・患者人口

第7章 要点

第8章 人口・予測パラメーター

第9章 NASHの有病者数:主要7ヶ国市場

第10章 地域別によるNASHの有病者数

第11章 NASH罹患者数:主要7ヶ国市場

第12章 地域別によるNASH罹患者数

  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第13章 治療アルゴリズム

第14章 American Association for the Study of Liver Diseases (AASLD) によるNAFLD/NASHへの現在の提言

第15章 EASL-EASD-EASO 非アルコール性脂肪肝疾患の管理に対する臨床診療ガイドライン

第16章 日本肝臓学会と連携した日本消化器がん検診学会 (JSG) によるNAFLD/NASHへのガイドライン

第17章 アンメットニーズ

第18章 新しい治療薬

  • 第III相医薬品分析
  • 第II相医薬品分析

第19章 新しい治療法

第20章 非アルコール性脂肪性肝炎 (NASH) :国別の市場分析

第21章 米国

第22章 欧州

第23章 ドイツ

第24章 フランス

第25章 イタリア

第26章 スペイン

第27章 英国

第28章 日本

第29章 市場成長促進因子

第30章 市場障壁

第31章 付録

第32章 調査手法

第33章 コンサルティングサービス

第34章 免責事項

第35章 DelveInsightについて

図表リスト

図表

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2027)
  • Table 4: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2027)
  • Table 5: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2027)
  • Table 6: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2027)
  • Table 7: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2027)
  • Table 8: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2027)
  • Table 9: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2027)
  • Table 10: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2027)
  • Table 11: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2027)
  • Table 12: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2027)
  • Table 13: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2027)
  • Table 14: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2027)
  • Table 15: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2027)
  • Table 16: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2027)
  • Table 17: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2027)
  • Table 18: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2027)
  • Table 19: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2027)
  • Table 20: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2027)
  • Table 21: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2027)
  • Table 22: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2027)
  • Table 23: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2027)
  • Table 24: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2027)
  • Table 25: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2027)
  • Table 26: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2027)
  • Table 27: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2027)
  • Table 28: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2027)
  • Table 29: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2027)
  • Table 30: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2027)
  • Table 31: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2027)
  • Table 32: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2027)
  • Table 33: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2027)
  • Table 34: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2027)
  • Table 35: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2027)
  • Table 36: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2027)
  • Table 37: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2027)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Table 42:7MM- Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 43:7MM- Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 44: United States-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Table 45: United States-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 46: United States-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 47: Germany-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Table 48: Germany-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 49: Germany-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 50: France-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Table 51: France-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 52: France-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 53: Italy-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Table 54: Italy-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 55: Italy-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 56: Spain-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Table 57: Spain-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 58: Spain-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 59:UK-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Table 60:UK-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 61:UK-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 62: Japan-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Table 63: Japan-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Table 64: Japan-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2027)
  • Figure 4: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2027)
  • Figure 5: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2027)
  • Figure 6: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2027)
  • Figure 7: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2027)
  • Figure 8: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2027)
  • Figure 9: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2027)
  • Figure 10: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2027)
  • Figure 11: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2027)
  • Figure 12: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2027)
  • Figure 13: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2027)
  • Figure 14: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2027)
  • Figure 15: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2027)
  • Figure 16: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2027)
  • Figure 17: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2027)
  • Figure 18: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2027)
  • Figure 19: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2027)
  • Figure 20: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2027)
  • Figure 21: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2027)
  • Figure 22: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2027)
  • Figure 23: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2027)
  • Figure 24: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2027)
  • Figure 25: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2027)
  • Figure 26: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2027)
  • Figure 27: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2027)
  • Figure 28: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2027)
  • Figure 29: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2027)
  • Figure 30: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2027)
  • Figure 31: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2027)
  • Figure 32: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2027)
  • Figure 33: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2027)
  • Figure 34: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2027)
  • Figure 35: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2027)
  • Figure 36: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2027)
  • Figure 37: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2027)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Figure 42:7MM- Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 43:7MM- Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 44: United States-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Figure 45: United States-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 46: United States-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 47: Germany-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Figure 48: Germany-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 49: Germany-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 50: France-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Figure 51: France-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 52: France-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 53: Italy-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Figure 54: Italy-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 55: Italy-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 56: Spain-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Figure 57: Spain-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 58: Spain-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 59:UK-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Figure 60:UK-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 61:UK-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 62: Japan-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2027)
  • Figure 63: Japan-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
  • Figure 64: Japan-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2027)
目次
Product Code: DIMI0019

DelveInsight's "Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Nonalcoholic Steatohepatitis (NASH) epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2027

Nonalcoholic Steatohepatitis (NASH) Understanding and Treatment Algorithm

The market report provides the overview of the Nonalcoholic Steatohepatitis (NASH) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Nonalcoholic Steatohepatitis (NASH) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Nonalcoholic Steatohepatitis (NASH) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Nonalcoholic Steatohepatitis (NASH) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Nonalcoholic Steatohepatitis (NASH) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Nonalcoholic Steatohepatitis (NASH) market.

Nonalcoholic Steatohepatitis (NASH) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Nonalcoholic Steatohepatitis (NASH) Report Insights

  • Patient Population in Nonalcoholic Steatohepatitis (NASH)
  • Therapeutic Approaches in Nonalcoholic Steatohepatitis (NASH)
  • Nonalcoholic Steatohepatitis (NASH) Pipeline Analysis
  • Nonalcoholic Steatohepatitis (NASH) Market Size and Trends
  • Nonalcoholic Steatohepatitis (NASH) Market Opportunities
  • Impact of upcoming Therapies in Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Nonalcoholic Steatohepatitis (NASH) Report Assessment

  • Current Treatment Practices in Nonalcoholic Steatohepatitis (NASH)
  • Unmet Needs in Nonalcoholic Steatohepatitis (NASH)
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Nonalcoholic Steatohepatitis (NASH) market
  • Organize sales and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis (NASH) market
  • To understand the future market competition in the Nonalcoholic Steatohepatitis (NASH) market.

Table of Contents

1. Report Introduction

2. Nonalcoholic Steatohepatitis (NASH) Market Overview at a Glance

  • 2.1. Market Share Distribution of Nonalcoholic Steatohepatitis (NASH) in 2017
  • 2.2. Market Share Distribution of Nonalcoholic Steatohepatitis (NASH) in 2027

3. Disease Background and Overview: Nonalcoholic Steatohepatitis (NASH)

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Nonalcoholic Steatohepatitis (NASH) in 7MM
  • 4.3. Total Prevalent Patient Population of Nonalcoholic Steatohepatitis (NASH) in 7MM - By Countries

5. Epidemiology of Nonalcoholic Steatohepatitis (NASH) by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.1.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.1.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.1.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.1.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.4.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.4.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.4.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.4.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.5.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.5.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.5.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.5.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.6.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.6.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.6.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.6.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.7.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.7.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.7.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.7.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.8.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.8.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.8.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.8.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.9.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.9.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
    • 5.9.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
    • 5.9.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Nonalcoholic Steatohepatitis (NASH)

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Nonalcoholic Steatohepatitis (NASH)

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Nonalcoholic Steatohepatitis (NASH) : 7MM Market Analysis

  • 12.1. 7MM Market Size of Nonalcoholic Steatohepatitis (NASH)
  • 12.2. 7MM Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH)
  • 12.3. 7MM Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products

13. Nonalcoholic Steatohepatitis (NASH) : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in United States
    • 13.1.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in United States
    • 13.1.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany

13.2.1.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in Germany

13.2.1.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in Germany

13.2.1.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in Germany

13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market

    • 13.2.2. France

13.2.2.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in France

13.2.2.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in France

13.2.2.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in France

13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

    • 13.2.3. Italy

13.2.3.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in Italy

13.2.3.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in Italy

13.2.3.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in Italy

13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

    • 13.2.4. Spain

13.2.4.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in Spain

13.2.4.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in Spain

13.2.4.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in Spain

13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

    • 13.2.5. United Kingdom

13.2.5.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in United Kingdom

13.2.5.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in United Kingdom

13.2.5.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

  • 13.3. Japan
    • 13.3.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in Japan
    • 13.3.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in Japan
    • 13.3.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

Back to Top